Although lorlatinib treatment has reportedly been more successful at delaying ALK inhibitor resistance compared with other ALK-TKIs, certain cancer models including relapsed ALK-F1174L neuroblastomas have been shown to eventually acquire resistance after long-term treatment (22–24, 45, 46). This evidence concerns the gene ALK and cancer.